Abstract:Background: Circulating methionine components have been reported to be associated with Alzheimer's disease (AD) and mild cognitive impairment (MCI), although outcomes are not always consistent. Materials and methods: Database searching was conducted using PubMed, Embase, Cochrane Library, and Web of Science from inception to 26 December 2021. In this study, two reviewers independently identified eligible articles and extracted the data. We used Joanna Briggs Institute (JBI) Critical Appraisal tools to assess the overall quality of the included studies. STATA software was employed to perform meta-analysis evaluating the standardized mean difference (SMD) with its 95% confidence intervals (CIs) using random-effects models. Evidence quality was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria. Results: Totally, 30 observational studies were eligible for inclusion. Compared with cognitively normal controls, patients with AD had increased homocysteine (Hcy) levels in the blood [standardized mean difference (SMD) = 0.59, 95% confidence interval [CI]: 0.36–0.82, P = 0.000], plasma (SMD = 0.39, 95% CI: 0.23–0.55, P = 0.000), and serum (SMD = 1.56, 95% CI: 0.59–2.95, P = 0.002). Patients with MCI were not significantly different from controls (SMD = 0.26, 95% CI: –0.07–0.58, P = 0.127). Patients with AD or MCI did not significantly differ from controls of blood vitamin B 12 levels, AD (SMD = –0.05, 95% CI: –0.19–0.08, P = 0.440), or MCI (SMD = 0.01, 95% CI: –0.16–0.17, P = 0.94). Some cohort studies have suggested that higher Hcy, methionine, and S -adenosylmethionine levels may accelerate cognitive decline in patients with MCI or AD, and vitamin B 12 deficiency is a risk factor for the disease; however, the results of other studies were inconsistent. According to the GRADE system, all these outcomes scored very low to low quality, and no high-quality evidence was found. Conclusion: Only Hcy levels in the plasma and serum were found to be inversely related to the risk of AD. However, due to the low quality of supporting these results, high-quality studies are needed to verify these findings. Systematic Review Registration: http://www.crd.york.ac.uk/PROSPERO/, identifier CRD42022308961.

Circulating arginine metabolites in Alzheimer’s disease and vascular dementia: A systematic review and meta-analysis

Targeted metabolomic analysis of nitric oxide/L-arginine pathway metabolites in dementia: association with pathology, severity, and structural brain changes

A systematic review and meta-analysis of nitric oxide-associated arginine metabolites in schizophrenia

Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of l-arginine on its metabolism

Arginine metabolomics in mood disorders

Relations Between Plasma Asymmetric Dimethylarginine (adma) and Risk Factors for Coronary Disease

Brain Arginine Metabolism in Early‐onset Alzheimer’s Disease and Frontotemporal Dementia

Impact of Nitric Oxide Bioavailability on the Progressive Cerebral and Peripheral Circulatory Impairments During Aging and Alzheimer's Disease

Blood levels of circulating methionine components in Alzheimer's disease and mild cognitive impairment: A systematic review and meta-analysis

Vascular nitric oxide may lessen Alzheimer's risk

L-Arginine and asymmetric dimethylarginine (ADMA) transport across the mouse blood-brain and blood-CSF barriers: evidence of saturable transport at both interfaces and CNS to blood efflux.

Asymmetric and symmetric dimethylarginine as markers of endothelial dysfunction in cerebrovascular disease: A prospective study

Urinary Dimethylamine (DMA) and Its Precursor Asymmetric Dimethylarginine (ADMA) in Clinical Medicine, in the Context of Nitric Oxide (NO) and Beyond

Intrathecal Release of Nitric Oxide in Alzheimer’s Disease and Vascular Dementia

Levels of Asymmetric Dimethylarginine (ADMA), an Endogenous Nitric Oxide Synthase Inhibitor, and Risk of Coronary Artery Disease: A Meta-Analysis Based on 4713 Participants.

The Gasotransmitter NO and H2S in Alzheimer′s disease

L-Arginine-Nitric Oxide-Asymmetric Dimethylarginine Pathway and the Coronary Circulation: Translation of Basic Science Results to Clinical Practice

Protein arginine methyltransferase 4 modulates nitric oxide synthase uncoupling and cerebral blood flow in Alzheimer's disease

Dysregulated Urinary Arginine Metabolism in Older Adults with Amnestic Mild Cognitive Impairment.

Asymmetric Dimethyarginine As Marker And Mediator In Ischemic Stroke

Oxidative stress in blood in Alzheimer's disease and mild cognitive impairment: a meta-analysis